Bharat Biotech on Sunday described the permission for emergency use of Covaxin, the company’s homegrown vaccine for Covid-19, as a “giant leap for innovation and novel product development in India”. Serum Institute of Indian (SII) said it is ready to roll out the Covishield vaccine in the coming weeks. “Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off. Covishield, India’s first Covid-19 vaccine is approved, safe, effective, and ready to roll-out in the coming weeks,” SII CEO Adar Poonawalla said in a Tweet.
Speaking to Hello Vizag, Bharat Biotech Chairman and Managing Director Krishna Ella said, “The approval of Covaxin for emergency use is a giant leap for innovation and novel product development in India. It is a proud moment for the nation and a great milestone in India’s scientific capability, a kick-start to the innovation ecosystem in India.”
While this vaccine addresses an unmet medical need during this pandemic, the company’s goal is to provide global access to populations that need it the most, Ella said. Covaxin has generated excellent safety data with robust immune responses to multiple viral proteins that persist.
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology. Bharat Biotech aims to recruit 26,000 volunteers across the country for the Phase-3 trials. It has crossed the 23,000 volunteer marks.
Get 30% OFF on Dynamic Website Design